Advertisement

Picture EBD Group BIO-Europe Spring 2021 Digital 650x80

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3112 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 10 11 12 ... 30 31 32  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Vaccitech–Minapharm: cell line, 201905– license to ProBioGen’s AGE1.CR duck cell line for production of viral vectored vaccines 2019-05-15
Icometrix–Bertarelli Group: investment, 201905 financing round totalling $18m incl new + lead investor Forestay Capital 2019-05-14
Icometrix–Capricorn Venture Partners: investment, 201905 financing round totalling $18m incl existing + co-investor Capricorn Venture Partners 2019-05-14
Icometrix–SEVERAL: investment, 201905 financing round $18m led by Forestay Capital + incl Optum Ventures + Capricorn Venture Partners 2019-05-14
Icometrix–UnitedHealth: investment, 201905 financing round totalling $18m incl new + co-investor Optum Ventures 2019-05-14
Philogen–Consilium: public relations, 201905 service existent by CSC 2019-05-13
Philogen–SEVERAL: investment, 201905 financing round €62m from existing + new private investors 2019-05-13
TreeFrog Therapeutics–SEVERAL: investment, 201905 financing round Series A €6.5m led by XAnge + incl Galia Geston et al 2019-05-13
Priavoid–PERSON: investment, 201905c Detlev Riesner recently acquired shares of Priavoid GmbH 2019-05-10
MabVax Therapeutics–BioNTech: investment, 201905 acquisition €na of antibody assets + infrastructure + lab equipment in San Diego 2019-05-08
Therachon–Cowen: investment, 201905 existing investor Cowen 2019-05-08
Therachon–France (govt): investment, 201905 existing investors Bpifrance + Inserm Transfert Initiative 2019-05-08
Therachon–Novo Group: investment, 201905 existing investor Novo Holdings 2019-05-08
Therachon–OrbiMed: investment, 201905 existing investor OrbiMed 2019-05-08
Therachon–Pfizer: investment, 201905 existing investor Pfizer Ventures 2019-05-08
Therachon–Pfizer: investment, 201905– acquisition 100% $340m upfront + $470m milestones excl apraglutide development program 2019-05-08
Therachon–Tekla Capital: investment, 201905 existing investor Tekla Capital Management LLC 2019-05-08
Therachon–Versant Ventures: investment, 201905 existing investor Versant Ventures 2019-05-08
Confo Therapeutics–SEVERAL: investment, 201905 financing round Series A €30m led by BGV + co-led by Wellington Partners 2019-05-07
Confo Therapeutics–Wellington Partners: investment, 201905 financing round Series A totalling €30m incl new + co-lead investor Wellington Partners 2019-05-07
DyNAbind–High-Tech Gründerfonds: investment, 201905 seed financing round incl new investor HTGF 2019-05-07
DyNAbind–Saxony (govt): investment, 201905 seed financing round incl new investor Technologiegründerfonds Sachsen 2019-05-07
DyNAbind–SEVERAL: investment, 201905 seed financing round from HTGF + TGFS + TUDAG 2019-05-07
DyNAbind–TU Dresden: investment, 201905 seed financing round incl existing investor TUDAG TU Dresden AG 2019-05-07
Merck (DE)–DyNAbind: drug discovery technology, 201905 collab existent marketing of DEL discovery kit with Merck KGaA 2019-05-07
Northwestern Univ–DyNAbind: drug discovery technology, 201905 collab existent with Northwestern Univ Chicago 2019-05-07
OMass–DyNAbind: drug discovery technology, 201905 collab existent with OMass Therapeutics 2019-05-07
Sosei–DyNAbind: drug discovery technology, 201905 collab existent with Sosei Heptares 2019-05-07
Cutech (IT)–Symrise: investment, 201905 acquisition of Cutech Srl by Symrise 2019-05-06
Intermolecular–Merck (DE): investment, 201905– acquisition of Intermolecular Inc by Merck for $62m in cash at $1.2/share 2019-05-06
Chemical Solutions Ltd–SGS: investment, 201905 acquisition of CSL by SGS 2019-05-03
Amal Therapeutics–Boehringer: cancer drugs, 201905– collab clinical research combi study of ATP128 + BI754091 in colorectal cancer 2019-05-02
CStone–Numab: antibody cancer drug, 201905– collab + license for tri-specific antibody ND021 in Greater China + KR + SG 2019-05-02
miRdetect–Bremen (govt): investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor 2019-05-02
miRdetect–High-Tech Gründerfonds: investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor 2019-05-02
miRdetect–OTHER: investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor 2019-05-02
miRdetect–SEVERAL: investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor 2019-05-02
Alentis Therapeutics–Bellevue: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BB Pureos Bioventures 2019-04-30
Alentis Therapeutics–BioMedPartners: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BioMedPartners 2019-04-30
Alentis Therapeutics–France (govt): investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Bpifrance 2019-04-30
Alentis Therapeutics–High-Tech Gründerfonds: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor HTGF 2019-04-30
Alentis Therapeutics–Instinctif Partners: public relations, 201904 service existent media relations by Instinctif 2019-04-30
Alentis Therapeutics–Schroders: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Schroder Adveq 2019-04-30
Alentis Therapeutics–SEVERAL: investment, 201904 financing round Series A CHF12.5m co-led by BioMedPartners + BB Pureos Bioventures 2019-04-30
SGS–Veeva Systems: clinical research software, 201904– supply global implementation of Veeva Vault CTMS by SGS 2019-04-30
Vividion Therapeutics–Nextech: investment, 201904 financing round Series B totalling $82m incl new + lead investor Nextech Invest 2019-04-30
Vividion Therapeutics–SEVERAL: investment, 201904 financing round Series B $82m led by new investor Nextech Invest 2019-04-30
Canopy Biosciences–Ampersand: investment, 201904 strategic growth investment from Ampersand Capital Partners 2019-04-29
Zellkraftwerk–Canopy Biosciences: investment, 201904 acquisition of Zellkraftwerk GmbH by Canopy Biosciences 2019-04-29
ADC Therapeutics–Adagene: antibody technology, 201904– collab + license agreem €na using SAFEbody technology for ADC development 2019-04-24
Chiome Bioscience–Velabs Therapeutics: antibody drug discovery, 201904– collab using Velabs’ microfluidcs techn for functional antibody screening 2019-04-24
InfanDx–Arnika Beteiligungen: investment, 201904 financing round totalling up to €5.3m incl existing + co-investor Arnika Beteiligungen GmbH 2019-04-24
InfanDx–Bamed MAM Group: investment, 201904 financing round totalling up to €5.3m incl new investor Bamed MAM Group 2019-04-24
InfanDx–CVG Capital: investment, 201904 financing round totalling up to €5.3m incl new investor CVG Capital GmbH 2019-04-24
InfanDx–Life Science Inkubator: investment, 201904 financing round totalling up to €5.3m incl existing + co-investor LSI-Pre-Seed-Fonds GmbH 2019-04-24
InfanDx–SEVERAL: investment, 201904 financing round up to €5.3m milestone-based from Bamed MAM + CVG Capital + LSI PreSeed + Arnika Beteiligungen 2019-04-24
Poseida Therapeutics–Novartis: investment, 201904 financing round Series C totalling $142m incl $75m from lead investor Novartis Pharma AG 2019-04-22
Poseida Therapeutics–SEVERAL: investment, 201904 financing round Series C $142m led by Novartis with $75m 2019-04-22
Arrakis Therapeutics–HBM: investment, 201904 financing round Series B totalling $75m incl new + co- investor HBM Healthcare Investments 2019-04-18
Arrakis Therapeutics–Nextech: investment, 201904 financing round Series B totalling $75m incl co-lead investor Nextech Invest 2019-04-18
Arrakis Therapeutics–SEVERAL: investment, 201904 financing round Series B $75m co-led by VenBio Partners + Nextech Invest 2019-04-18
Boehringer–PureTech Health: cancer immunotherapy, 201904– colllab research up to $226m + royalties using lymphatic targeting platform for I-O drugs 2019-04-17
Hookipa–Bank of America: financial services, 201904 supply service BofA Merrill Lynch is joint book-running manager for IPO 2019-04-17
Hookipa–RBC Capital Markets: financial services, 201904 supply service RBC Capital Markets is joint book-running manager for IPO 2019-04-17
Hookipa–SVB: financial services, 201904 supply service SVP Leerink is joint book-running manager for IPO 2019-04-17
Hookipa–Van Lanschot: financial services, 201904 supply service Kempen is co-manager for IPO 2019-04-17
Bruker–Univ Nijmegen: mass spectrometry, 201904– collab establishment of joint Center of Excellence for Translational Omics at RUMC TML 2019-04-16
Cevec–SEVERAL: investment, 201904 financing round Series D from new + existing investors 2019-04-16
DNDi–Atomwise: AI-based drug discovery, 201904 collab existent €0 screening + discovery of potential drugs for Chagas disease at no cost for DNDi 2019-04-16
Univ Nijmegen–Bruker: mass spectrometer, 201904 supply existent several Bruker MS systems at RUMC TML 2019-04-16
Univ Nijmegen–Bruker: mass spectrometer, 201904c supply acquisition of timsTOF Pro IM-MS system by RUMC TML 2019-04-16
ETH Zürich–Agilent: mass spectrometer, 201904 supply new 6546 LC/Q-TOF MS system to lab of Nicola Zamboni 2019-04-15
Gilead–Novo Group: drug development, 201904– collab clinical research for NASH combining semaglutide + cilofexor + firsocostat Novo Nordisk 2019-04-12
Evotec–Indivumed: cancer drug discovery, 201904– collab strategic precision medicine for new colorectal cancer drugs 2019-04-11
BioAnalytix–Zukunftsfonds Heilbronn: investment, 201904 merger acquisition of BioAnalytix Inc by Protagen Protein Services GmbH 2019-04-10
DKSH–Bruker: analytical instruments, 201904– distribution excl extension for Bruker AXS products by DKSH in China 2019-04-09
Probiodrug–SEVERAL: investment, 201904 private placement €8.2m net €7.65m with 4.1m new shares at €2m led by Claus Christiansen et al. 2019-04-09
Phenex–Helmholtz: drug research, 201904– collab joint research in NASH + liver cancer metabolism with Heikenwälder Group at DKFZ 2019-04-05
AgomAb Therapeutics–Advent France Biotechnology: investment, 201904 financing round Series A totalling €21m incl co-lead investor Advent France 2019-04-03
AgomAb Therapeutics–Boehringer: investment, 201904 financing round Series A totalling €21m incl co-investor BIVF 2019-04-03
AgomAb Therapeutics–Omnes Capital: investment, 201904 financing round Series A totalling €21m incl co-investor Omnes 2019-04-03
AgomAb Therapeutics–Pontifax: investment, 201904 financing round Series A totalling €21m incl co-investor Pontifax 2019-04-03
AgomAb Therapeutics–SEVERAL: investment, 201904 financing round Series A €21m co-led by V-Bio Ventures + Advent France Biotechnology 2019-04-03
AgomAb Therapeutics–V-Bio Ventures: investment, 201904 financing round Series A totalling €21m incl co-lead investor V-Bio Ventures 2019-04-03
Bayer–Editas Medicine: genome editing + cell therapy, 201904– strategic research collab + cross-license CRISPR + iPSC technologies BlueRock Tx 2019-04-03
Dyne Therapeutics–Atlas Venture: investment, 201904 financing round Series A totalling $50m incl founding investor Atlas Venture 2019-04-03
Dyne Therapeutics–Forbion: investment, 201904 financing round Series A totalling $50m incl co-investor Forbion 2019-04-03
Dyne Therapeutics–MPM Capital: investment, 201904 financing round Series A totalling $50m incl co-investor MPM Capital 2019-04-03
Dyne Therapeutics–SEVERAL: investment, 201904 financing round Series A $50m from founding investor Atlas Venture plus Forbion + MPM Capital 2019-04-03
LabCorp–Qiagen: molecular companion diagnostics, 201904– collab LabCorp joins Qiagen’s Day-One Lab Readiness program 2019-04-03
Rave LLC–Bruker: investment, 201904 acquisition €na by Bruker 2019-04-03
Chr. Hansen–Lonza: microbiomic treatment, 201904– collab establishment 50/50 joint venture for developing + manufacturing microbiome treatments 2019-04-02
Immunic–Rx Communications: public relations, 201904 service existent by Rx Communications Group 2019-04-02
Khloris Biosciences–Bayer: investment, 201904 seed financing €na from Leaps by Bayer 2019-04-02
IFM Therapeutics–Novartis: investment, 201904– acquisition 100% of IMF Tre for $1.6b incl upfront payment + milestones ANNOUNCED 2019-04-01
Bayer–ProteoNic: rec protein production technology, 201903– license non-excl €na to use 2G UNic technology to boost rec protein production 2019-03-28
Polyneuron–New Enterprise Associates: investment, 201903 financing round Series A totalling CHF22.5m incl new + co-lead investor NEA 2019-03-28
Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA 2019-03-28
Polyneuron–Sofinnova: investment, 201903 financing round Series A totalling CHF22.5m incl new + lead investor Sofinnova Partners 2019-03-28
Breath Therapeutics–Canale Communications: public relations, 201903 service existent for US by Canale Communciations Inc 2019-03-26
next pagenext page 1 2 3 ... 10 11 12 ... 30 31 32  next pagenext page



Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] No Content Marketing 650x80px

» top